IRWD Relative Valuation
IRWD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, IRWD is overvalued; if below, it's undervalued.
Historical Valuation
Ironwood Pharmaceuticals Inc (IRWD) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 14.36. The fair price of Ironwood Pharmaceuticals Inc (IRWD) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：3.62
Fair
8.67
PE
1Y
3Y
5Y
Trailing
Forward
6.11
EV/EBITDA
Ironwood Pharmaceuticals Inc. (IRWD) has a current EV/EBITDA of 6.11. The 5-year average EV/EBITDA is 9.94. The thresholds are as follows: Strongly Undervalued below -2.84, Undervalued between -2.84 and 3.55, Fairly Valued between 16.32 and 3.55, Overvalued between 16.32 and 22.71, and Strongly Overvalued above 22.71. The current Forward EV/EBITDA of 6.11 falls within the Historic Trend Line -Fairly Valued range.
7.27
EV/EBIT
Ironwood Pharmaceuticals Inc. (IRWD) has a current EV/EBIT of 7.27. The 5-year average EV/EBIT is 10.13. The thresholds are as follows: Strongly Undervalued below -2.86, Undervalued between -2.86 and 3.64, Fairly Valued between 16.62 and 3.64, Overvalued between 16.62 and 23.11, and Strongly Overvalued above 23.11. The current Forward EV/EBIT of 7.27 falls within the Historic Trend Line -Fairly Valued range.
1.96
PS
Ironwood Pharmaceuticals Inc. (IRWD) has a current PS of 1.96. The 5-year average PS is 3.33. The thresholds are as follows: Strongly Undervalued below 0.32, Undervalued between 0.32 and 1.82, Fairly Valued between 4.83 and 1.82, Overvalued between 4.83 and 6.34, and Strongly Overvalued above 6.34. The current Forward PS of 1.96 falls within the Historic Trend Line -Fairly Valued range.
3.68
P/OCF
Ironwood Pharmaceuticals Inc. (IRWD) has a current P/OCF of 3.68. The 5-year average P/OCF is 7.60. The thresholds are as follows: Strongly Undervalued below -1.79, Undervalued between -1.79 and 2.91, Fairly Valued between 12.30 and 2.91, Overvalued between 12.30 and 17.00, and Strongly Overvalued above 17.00. The current Forward P/OCF of 3.68 falls within the Historic Trend Line -Fairly Valued range.
3.68
P/FCF
Ironwood Pharmaceuticals Inc. (IRWD) has a current P/FCF of 3.68. The 5-year average P/FCF is 6.70. The thresholds are as follows: Strongly Undervalued below -2.07, Undervalued between -2.07 and 2.32, Fairly Valued between 11.08 and 2.32, Overvalued between 11.08 and 15.46, and Strongly Overvalued above 15.46. The current Forward P/FCF of 3.68 falls within the Historic Trend Line -Fairly Valued range.
Ironwood Pharmaceuticals Inc (IRWD) has a current Price-to-Book (P/B) ratio of -2.30. Compared to its 3-year average P/B ratio of -1.69 , the current P/B ratio is approximately 35.73% higher. Relative to its 5-year average P/B ratio of 6.50, the current P/B ratio is about -135.33% higher. Ironwood Pharmaceuticals Inc (IRWD) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 21.34%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 17.81% , the current FCF yield is about -100.00% lower.
-2.30
P/B
Median3y
-1.69
Median5y
6.50
11.15
FCF Yield
Median3y
21.34
Median5y
17.81
Competitors Valuation Multiple
The average P/S ratio for IRWD's competitors is 0.00, providing a benchmark for relative valuation. Ironwood Pharmaceuticals Inc Corp (IRWD) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 33.26%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of IRWD decreased by 15.80% over the past 1 year. The primary factor behind the change was an increase in Margin Expansion from 3.98 to 32.84.
The secondary factor is the Revenue Growth, contributed 33.26%to the performance.
Overall, the performance of IRWD in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is Ironwood Pharmaceuticals Inc (IRWD) currently overvalued or undervalued?
What is Ironwood Pharmaceuticals Inc (IRWD) fair value?
How does IRWD's valuation metrics compare to the industry average?
What is the current P/B ratio for Ironwood Pharmaceuticals Inc (IRWD) as of Dec 05 2025?
What is the current FCF Yield for Ironwood Pharmaceuticals Inc (IRWD) as of Dec 05 2025?
What is the current Forward P/E ratio for Ironwood Pharmaceuticals Inc (IRWD) as of Dec 05 2025?